JinMatrix Obtains US Patent for Multiplex Molecular Diagnostic Core Technology

[Asia Economy Reporter Moon Hyewon] JinMatrix announced on the 8th that it has obtained a US patent for its proprietary multiplex molecular diagnostic core technology, ‘C-Tag’.

The patented technology is a platform used in the Neoplex multiplex molecular diagnostic product line. The company explained that it is recognized as a next-generation core technology capable of advanced multiplexing, surpassing the previously known limit of up to five simultaneous analyses in conventional real-time PCR technology.

JinMatrix is currently preparing a comprehensive respiratory virus panel rapid diagnostic product applying the C-Tag core technology to its COVID-19 diagnostic products, which are being exported to Europe, the Middle East, and other regions.